TB-500 Research: What 114 Studies Show (2026) | RetatrutideCompare

TB-500 — 114 studies indexed on PubMed. Binds G-actin and influences cell migration, angiogenesis, fibroblast and stem-cell recruitment; modulates inflammation in injury models. Half-life: ~2 hours (fragment); ~12 hours (full TB-4). FDA status: Not FDA-approved (full TB-4 is in clinical trials for dry eye and post-MI).

PubMed search-result count last fetched 2026-06-18. Records may include reviews, laboratory work, and animal studies; this is not a clinical trial count or a measure of efficacy.

Inspect the PubMed query and results

How many studies have been published on TB-500?

There are approximately 114 studies indexed on PubMed that mention TB-500 (Thymosin Beta-4 fragment, TB4 Frag 17-23), based on a search last updated 2026-06-18.

Is TB-500 FDA-approved?

FDA status: Not FDA-approved (full TB-4 is in clinical trials for dry eye and post-MI).

How does TB-500 work?

Binds G-actin and influences cell migration, angiogenesis, fibroblast and stem-cell recruitment; modulates inflammation in injury models.

Reference facts

Also known as: Thymosin Beta-4 fragment, TB4 Frag 17-23
Category: Healing & Tissue Repair
Mechanism of action: Binds G-actin and influences cell migration, angiogenesis, fibroblast and stem-cell recruitment; modulates inflammation in injury models.
Targets: G-actin, Angiogenic signaling
Indications under research or approved: Research only — soft tissue, tendon, corneal healing
Regulatory status (reference entry): Not FDA-approved (full TB-4 is in clinical trials for dry eye and post-MI)
Half-life: ~2 hours (fragment); ~12 hours (full TB-4)
Sequence: LKKTETQ
Sequence notes: Synthetic peptide marketed as the active fragment of Thymosin Beta-4 (residues 17-23). Some research vials are labeled TB-500 but contain full-length TB-4 (43 aa).
Molecular weight (Da): 889
First reported: 2000

Primary References

Goldstein, Ann NY Acad Sci 2007 (Thymosin Beta-4)

Explore research articles about TB-500

This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.